½ÃÀ庸°í¼­
»óǰÄÚµå
1429282

¼¼°è Ź½ÃÆú¸° ½ÃÀå : ÇöȲ ºÐ¼®°ú ¿¹Ãø(2023-2030³â)

Taxifolin Market: Current Analysis and Forecast (2023-2030)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: UnivDatos Market Insights Pvt Ltd | ÆäÀÌÁö Á¤º¸: ¿µ¹® 158 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Ź½ÃÆú¸° ½ÃÀåÀº °Ç°­°ú À£´Ï½º »ê¾÷ÀÇ ¼ºÀåÀ¸·Î CAGR ¾à 6.1%ÀÇ °­·ÂÇÑ ¼ºÀåÀÌ ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °Ç°­¿¡ ÇØ·Î¿î ¶óÀÌÇÁ ½ºÅ¸ÀÏ·Î ÀÎÇÑ ¿°Áõ¼º Áúȯ Áõ°¡´Â Ź½ÃÆú¸° ½ÃÀå ¼ö¿ä Áõ°¡¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Ź½ÃÆú¸°Àº Ç׿°Áõ ÀÛ¿ëÀ» ³ªÅ¸³»°í, ¿°Áõ¼º ºÐÀÚÀÇ »ý»êÀ» ¾ïÁ¦Çϰí, °ÇÀüÇÑ ¿°Áõ ¹ÝÀÀÀ» ÃËÁøÇÕ´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ±¹¸³À§»ý¿¬±¸¼Ò°¡ Ź½ÃÆú¸°¿¡ ´ëÇØ ½Ç½ÃÇÑ ¿¬±¸¿¡ µû¸£¸é, Ź½ÃÆú¸°Àº »êÈ­ ½ºÆ®·¹½º ¹× ¿°Áõ ¹ÝÀÀ¿¡ °ü¿©ÇÏ´Â ´Ù¾çÇÑ ¹°ÁúÀ» Á¦¾îÇÔÀ¸·Î½á RAW264.7 ¼¼Æ÷¿¡ ºÎ¿©µÈ ¿°Áõ¼º ÇÇÇØ¸¦ °³¼±ÇÑ´Ù ´É·ÂÀ» °¡Áö°í ÀÖÀ½À» ½Ã»çÇÕ´Ï´Ù. À̰ÍÀº Ź½ÃÆú¸°ÀÌ ¿°Áõ¼º ÁúȯÀÇ Ä¡·á ¿µ¿ª¿¡¼­ Ãß°¡ ¿¬±¸°¡ ±â´ëµÈ´Ù´Â °ÍÀ» º¸¿©ÁÝ´Ï´Ù. ÀÌ Æ¯¼ºÀ¸·Î ÀÎÇØ Ź½ÃÆú¸°Àº °üÀý¿°, õ½Ä ¹× ƯÁ¤ ÇǺΠÁúȯ°ú °°Àº ¿°Áõ¼º Áúȯ°ú °ü·ÃµÈ Áõ»óÀ» ¿ÏÈ­ÇÏ´Â µ¥ ÀáÀçÀûÀ¸·Î °¡Ä¡ÀÖ´Â ¼ººÐÀ̵˴ϴÙ.

¼øµµ¿¡ µû¶ó ½ÃÀåÀº 95% ¹Ì¸¸°ú 95% ÀÌ»óÀ¸·Î 2ºÐÇÒ ¼ö ÀÖ½À´Ï´Ù. ¼øµµ 95% ¹Ì¸¸ÀÇ Å¹½ÃÆú¸°ÀÌ ÃÖ´ë Á¡À¯À²·Î ½ÃÀåÀ» µ¶Á¡Çϰí ÀÖ½À´Ï´Ù. ¼øµµ 95% ¹Ì¸¸ÀÇ Å¹½ÃÆú¸°ÀÌ ¿ìÀ§¸¦ Â÷ÁöÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â ±× ºñ¿ë ´ëºñ È¿°úÀÔ´Ï´Ù. Àú¼øµµÀÇ Å¹½ÃÆú¸°Àº ÀϹÝÀûÀ¸·Î Á¦Á¶ ºñ¿ëÀÌ Àú·ÅÇϱ⠶§¹®¿¡ Á¦Á¶ÀÚ¿¡°Ô º¸´Ù Àú·ÅÇÑ °¡°ÝÀÌ µÇ°í, º¸´Ù ¸¹Àº °í°´ÃþÀ» ²ø¾îµéÀδÙ. °Ô´Ù°¡ Ź½ÃÆú¸°Àº ÀǾàǰ, È­Àåǰ, ½ÄÀ½·á µî ´Ù¾çÇÑ »ê¾÷¿¡¼­ ÀÀ¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀϺΠ¿ëµµ¿¡¼­´Â Á¦Ç°ÀÇ Ç°Áú°ú È¿´ÉÀ» ¼Õ»ó½ÃŰÁö ¾Ê°í ¼øµµ°¡ ³·Àº Ź½ÃÆú¸°À¸·Î ÃæºÐÇÕ´Ï´Ù. ÀÌ È£È¯¼ºÀ» ÅëÇØ Á¦Á¶¾÷ü´Â ¸¹Àº ÀÀ¿ë ºÐ¾ß¿¡ 95% ÀÌÇÏÀÇ ¼øµµÀÇ Å¹½ÃÆú¸°À» Á¦°øÇÏ¿© ½ÃÀå ¿ä±¸¿¡ ºÎÀÀÇÒ ¼ö ÀÖ½À´Ï´Ù.

¿ëµµ¿¡ µû¶ó ½ÃÀåÀº À½½Ä, È­Àåǰ, °Ç°­ °ü¸® ¹× ³ó¾÷À¸·Î ±¸ºÐµË´Ï´Ù. ½ÄÀ½·á »ê¾÷Àº Ź½ÃÆú¸° ½ÃÀå¿¡¼­ ÁÖ¿ä ¼ÒºñÀÚ Áß ÇϳªÀÔ´Ï´Ù. ½ÄÀ½·á »ê¾÷¿¡¼­ Ź½ÃÆú¸° ¼ö¿ä¸¦ ³ôÀ̰í ÀÖ´Â ÁÖ¿ä ¿äÀÎÀº ¼ÒºñÀÚÀÇ °Ç°­ ÁöÇâ Áõ°¡À̸ç, À½½Ä ¹× À½·á Á¦Á¶¾÷ü´Â Á¦Ç°ÀÇ ¿µ¾ç°¡¸¦ ³ôÀ̱â À§ÇØ Å¹½ÃÆú¸°À» µµÀÔÇϵµ·Ï µÇ¾î ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ź½ÃÆ÷¸°ÀÇ Ç×±Õ¡¤Ç׿°Áõ Ư¼º¿¡ ÀÇÇØ ´Ù¾çÇÑ Á¦Ç°ÀÇ º¸Á¸ ±â°£À» ¿¬ÀåÇÏ´Â È¿°úÀûÀΠõ¿¬ º¸Á¸·á°¡ µÇ°í ÀÖ½À´Ï´Ù. Ź½ÃÆú¸°Àº ºÎÆÐÀÇ ¿øÀÎÀÌ µÇ´Â ¹Ì»ý¹°ÀÇ Áõ½ÄÀ» ¾ïÁ¦ÇÔÀ¸·Î½á Á¦Ç°ÀÇ ½Å¼±µµ¸¦ È®º¸ÇÏ°í Æó±â¹°À» ÃÖ¼ÒÈ­ÇÏ´Â ±ÍÁßÇÑ Åø·Î¼­ µîÀåÇϰí, ÀÌ·¯ÇÑ ¿äÀÎÀÌ ½ÄÀ½·á ¾÷°è¿¡¼­ÀÇ Å¹½ÃÆú¸° ¼ö¿ä Áõ°¡¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

Ź½ÃÆú¸° ½ÃÀå µµÀÔ¿¡ ´ëÇÑ ÀÌÇØ¸¦ ³ôÀ̱â À§ÇØ ½ÃÀåÀº ºÏ¹Ì(¹Ì±¹, ij³ª´Ù, ±âŸ ºÏ¹Ì), À¯·´(µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ½ºÆäÀÎ, ÀÌÅ»¸®¾Æ, ±âŸ À¯·´), ¾Æ½Ã¾ÆÅÂÆò¾ç(Áß±¹, ÀϺ», Àεµ, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç), ¼¼°è ±âŸ Áö¿ª¿¡¼­ ¼¼°èÀÇ Á¸À縦 ±â¹ÝÀ¸·Î ºÐ¼®µË´Ï´Ù. ¾Æ½Ã¾ÆÅÂÆò¾çÀº Ź½ÃÆú¸° Á¦Ç°ÀÇ ±Þ¼ºÀå ½ÃÀå Áß Çϳª·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. Ź½ÃÆú¸° Á¦Ç°ÀÇ °í¼ºÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª´Â ¿µ¾ç º¸Á¶ ½Äǰ »ê¾÷ÀÇ ¼ºÀåÀÔ´Ï´Ù. Ź½ÃÆú¸°Àº ÀáÀçÀûÀÎ °Ç°­ È¿°ú·Î ÀÎÇØ ÀÌ·¯ÇÑ Á¦Ç°ÀÇ À¯È¿ ¼ººÐÀ¸·Î »ç¿ëµÇ¸ç ¼ö¿ä¸¦ ´õ¿í ¹Ð¾î ¿Ã¸®°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÀÌ Áö¿ª¿¡¼­´Â ½ÉÇ÷°ü Áúȯ, ´ç´¢º´, ¾Ï µîÀÇ ¸¸¼º ÁúȯÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Ź½ÃÆú¸°ÀÇ ÀÌ·¯ÇÑ Áúº´¿¡ ´ëÇÑ ÀáÀçÀûÀÎ ¿¹¹æ È¿°ú´Â ±â´É¼º ½Äǰ°ú À½½Ä¿¡ »ç¿ëÀ» ÃËÁøÇÏ°í ¼ÒºñÀÚÃþÀÇ È®´ë¸¦ À̲ø¾î ³À´Ï´Ù. ¶ÇÇÑ, ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿©·¯ ³ª¶ó¿¡¼­ °¡Ã³ºÐ ¼ÒµæÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¼ÒºñÀÚ´Â ÇÁ¸®¹Ì¾ö °Ç°­ Á¦Ç°¿¡ ÅõÀÚÇÏ´Â ±¸¸Å·ÂÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. À¯ÀÍÇÑ ¼ººÐÀ¸·Î ÀÚ¸®¸Å±èÇϴ Ź½ÃÆú¸°Àº ÀÌ µ¿Çâ¿¡ ´ëÀÀÇϱâ À§ÇØ º¸´Ù °íǰÁúÀÇ Á¦Ç°¿¡ ÅëÇյǰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ÃÀå ¼Ò°³

  • ½ÃÀåÀÇ Á¤ÀÇ
  • ÁÖ¿ä ¸ñÇ¥
  • ÀÌÇØ°ü°èÀÚ
  • Á¦ÇÑ »çÇ×

Á¦2Àå Á¶»ç ¹æ¹ý ¶Ç´Â ÀüÁ¦

  • Á¶»ç °úÁ¤
  • Á¶»ç ¹æ¹ý
  • ÀÀ´äÀÚ ÇÁ·ÎÆÄÀÏ

Á¦3Àå ½ÃÀå ¿ä¾à

Á¦4Àå ÁÖ¿ä ¿ä¾à

Á¦5Àå COVID-19°¡ Ź½ÃÆú¸° ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâ

Á¦6Àå Ź½ÃÆú¸° ½ÃÀå ¼öÀÍ(2020-2030³â)

Á¦7Àå ¼øµµº° ½ÃÀå ÀλçÀÌÆ®

  • 95% ¹Ì¸¸
  • 95% ÀÌ»ó

Á¦8Àå ¿ëµµº° ½ÃÀå ÀλçÀÌÆ®

  • À½½Ä
  • È­Àåǰ
  • ÇコÄɾî
  • ³ó¾÷

Á¦9Àå Áö¿ªº° ½ÃÀå ÀλçÀÌÆ®

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ±âŸ ºÏ¹Ì
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¼¼°è ±âŸ Áö¿ª

Á¦10Àå Ź½ÃÆú¸° ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀåÀÇ °úÁ¦
  • ¿µÇ⠺м®

Á¦11Àå Ź½ÃÆú¸° ½ÃÀå ±âȸ

Á¦12Àå Ź½ÃÆú¸° ½ÃÀå µ¿Çâ

Á¦13Àå ¼ö¿äÃø°ú °ø±ÞÃø ºÐ¼®

  • ¼ö¿äÃø ºÐ¼®
  • °ø±ÞÃø ºÐ¼®

Á¦14Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦15Àå °æÀï ½Ã³ª¸®¿À

  • °æÀï ±¸µµ
    • Porter's Five Forces ºÐ¼®

Á¦16Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Ametis JSC
  • JW Health Products Pty Ltd
  • Cayman Chemical
  • Ebrator Biochemicals
  • Adooq Bioscience LLC.
  • Creative Enzymes.
  • BOC Sciences
  • Nature Science Technologies
  • Alfa Chemistry
  • United States Biological

Á¦17Àå ¸éÃ¥»çÇ×

JHS 24.03.04

Taxilfolin, also known as TFX or Taxilfolin Extract, is a natural compound derived from a specific plant species known as Taxilfolia Vulgaris, which is predominantly found in the eastern Laos region. Taxilfolin is primarily popular for its potent antioxidant properties, which enable it to neutralize harmful free radicals within the body. This antioxidant activity aids in preventing cellular damage, reducing oxidative stress, and maintaining overall cellular health. Consequently, taxilfolin is thought to contribute to the prevention and management of various chronic diseases.

The Taxifolin Market is expected to grow at a strong CAGR of around 6.1% owing to the growing health and wellness industry. Furthermore, rising inflammatory diseases among the population due to unhealthy and sedentary lifestyles are playing a pivotal role in the growing demand for taxifolin in the market. Taxilfolin exhibits anti-inflammatory effects, inhibiting the production of pro-inflammatory molecules and promoting a healthy inflammatory response. For instance, the study done on taxifolin by the National Institutes of Health suggests that taxifolin possesses the ability to improve the inflammatory damage inflicted upon RAW264.7 cells by regulating various agents involved in oxidative stress and inflammatory reactions. This indicates that taxifolin holds immense promise for further investigation in the realm of treating inflammatory disorders. This characteristic makes taxifolin a potentially valuable component in alleviating symptoms associated with inflammatory conditions such as arthritis, asthma, and certain skin conditions.

Based on purity, the market is bifurcated into less than 95% and greater than equal to 95%. Taxifolin with purity less than 95% dominates the market with the largest share. One of the primary factors driving the dominance of taxifolin with a purity of less than 95% is its cost-effectiveness. Lower purity forms of taxifolin are generally cheaper to produce, making them more affordable for manufacturers, and attracting a larger customer base. Furthermore, Taxifolin finds applications in various industries, including pharmaceuticals, cosmetics, and food and beverages. For several applications, taxifolin with lower purity can suffice without compromising product quality or efficacy. This compatibility enables manufacturers to meet market demands by providing taxifolin with purity levels below 95%, which is sufficient for many applications.

Based on application, the market is segmented into foods and beverages, cosmetics, healthcare, and agriculture. The food and beverages industry is one of the predominant consumers of the taxifolin in the market. The primary factor that is driving the high demand for taxifolin in the food and beverages industry is the growing consumer demand for healthier food options, pushing food and beverage manufacturers to increasingly incorporate taxifolin to enhance the nutritional value of their products. Furthermore, Taxifolin's antimicrobial and anti-inflammatory properties have made it an effective natural preservative, aiding in extending the shelf life of various products. By inhibiting the growth of spoilage-causing microorganisms, taxifolin has emerged as a valuable tool for ensuring product freshness and minimizing waste, factors like these have played a vital role in the growing demand for taxifolin in the foods and beverages industry.

For a better understanding of the market adoption of taxifolin, the market is analyzed based on its worldwide presence in countries such as North America (The U.S., Canada, and the Rest of North America), Europe (Germany, The U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. Asia Pacific is emerging as one of the fastest-growing markets for taxifolin products. One of the primary factors that is driving the high growth of taxifolin products is the growing nutraceutical and dietary supplements industry. Taxifolin is being used as an active ingredient in these products due to its potential health benefits, further driving up the demand. Furthermore, the region has observed an increase in chronic diseases such as cardiovascular diseases, diabetes, and cancer. Taxifolin's potential protective effects against these conditions have prompted its usage in functional foods and beverages, attracting a growing consumer base. Additionally, as disposable incomes rise in many countries across the Asia Pacific, consumers have more purchasing power to invest in premium health products. Taxifolin, positioned as a beneficial ingredient, is being incorporated into higher-quality products to cater to this trend.

Some of the major players operating in the market include Ametis JSC; JW Health Products Pty Ltd; Cayman Chemical; Ebrator Biochemicals; Adooq Bioscience LLC.; Creative Enzymes.; BOC Sciences; Nature Science Technologies; Alfa Chemistry; and United States Biological

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Taxifolin Market
  • 2.2. Research Methodology of the Taxifolin Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE TAXIFOLIN MARKET

6 TAXIFOLIN MARKET REVENUE (USD BN), 2020-2030F.

7 MARKET INSIGHTS BY PURITY

  • 7.1. Less than 95%
  • 7.2. Greater than equal to 95%

8 MARKET INSIGHTS BY APPLICATION

  • 8.1. Food and Beverages
  • 8.2. Cosmetics
  • 8.3. Healthcare
  • 8.4. Agriculture

9 MARKET INSIGHTS BY REGION

  • 9.1. North America
    • 9.1.1. The U.S.
    • 9.1.2. Canada
    • 9.1.3. Rest of North America
  • 9.2. Europe
    • 9.2.1. Germany
    • 9.2.2. The U.K.
    • 9.2.3. France
    • 9.2.4. Italy
    • 9.2.5. Spain
    • 9.2.6. Rest of Europe
  • 9.3. Asia-Pacific
    • 9.3.1. China
    • 9.3.2. India
    • 9.3.3. Japan
    • 9.3.4. South Korea
    • 9.3.5. Rest of Asia-Pacific
  • 9.4. Rest of the World

10 TAXIFOLIN MARKET DYNAMICS

  • 10.1. Market Drivers
  • 10.2. Market Challenges
  • 10.3. Impact Analysis

11 TAXIFOLIN MARKET OPPORTUNITIES

12 TAXIFOLIN MARKET TRENDS

13 DEMAND AND SUPPLY-SIDE ANALYSIS

  • 13.1. Demand Side Analysis
  • 13.2. Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 COMPETITIVE SCENARIO

  • 15.1. Competitive Landscape
    • 15.1.1. Porters Fiver Forces Analysis

16 COMPANY PROFILED

  • 16.1. Ametis JSC
  • 16.2. JW Health Products Pty Ltd
  • 16.3. Cayman Chemical
  • 16.4. Ebrator Biochemicals
  • 16.5. Adooq Bioscience LLC.
  • 16.6. Creative Enzymes.
  • 16.7. BOC Sciences
  • 16.8. Nature Science Technologies
  • 16.9. Alfa Chemistry
  • 16.10. United States Biological

17 DISCLAIMER

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦